You just read:

CLJI Worldwide Trial Enrolls First Patient in Clinical Study Evaluating the Performance of VIBLOK as a Barrier for Herpes Simplex Virus Transmission in Men and Women

News provided by

CLJI Worldwide

May 23, 2017, 08:30 ET